Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

This is a multicenter, international, open-label, single-arm phase II clinical trial designed to evaluate the activity and safety of a combination therapy with pirtobrutinib and rituximab (P-R) in treatment-naïve adult patients diagnosed with indolent clinical forms of Mantle Cell Lymphoma (MCL). The study applies a Simon's two-stage design, with an interim analysis after the first 16 patients to determine continuation based on complete remission rate (CRR) after 6 cycles.

Trial Details

NCT ID
NCT07285590
Phase
PHASE2
Sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • Pirtobrutinib and rituximab
Locations (sample)
  • Lisbon, Lisbon District, Portugal|38.72509,-9.1498
  • Lisbon, Lisbon District, Portugal|38.72509,-9.1498
  • Badalona, Barcelona, Spain|41.45004,2.24741
  • Barcelona, Barcelona, Spain|41.38879,2.15899
  • Barcelona, Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Adult patients (≥18 years of age).
  • Written informed consent must be obtained before any study-specific assessment is performed.
  • Subjects with confirmed diagnosis of Mantle Cell Lymphoma according to the International Consensus Classification, (ICC) 2022\] or World Health Org…
  • Naïve patients for MCL management (no prior therapies, excluding diagnostic splenectomy)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →